The first agent in this class was approved in 2005 for type 2 diabetes, and ongoing studies continue to look at their broader applications, long-term benefits and safety profile
If you see bubbles, tap the syringe barrel gently with your fingernail
"Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients"
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes [1] [2]
Levels Take: Ultimately, GLP1 medications are not a sustainable solution to obesity or poor metabolic health for the vast majority of people
If you are microdosing to save money, do not push a pen past the eight-week mark